Last updated: February 25, 2026
Case Overview
Quest Diagnostics Investments LLC filed a patent infringement lawsuit against Laboratory Corporation of America Holdings (LabCorp) in the U.S. District Court for the District of Delaware. The complaint (filed February 2, 2018) alleges LabCorp infringed on patents related to molecular diagnostic testing methods.
Alleged Patent Rights
The case focuses on U.S. Patent Nos. 9,962,189; 10,031,254; and 10,089,129. These patents cover methods of detecting genetic variants using polymerase chain reaction (PCR) and high-throughput sequencing.
Patent Claims
- '189 Patent: Methods for detecting specific nucleotide sequences within genetic samples.
- '254 Patent: Systems for analyzing multiple target sequences simultaneously.
- '129 Patent: Techniques for reducing false positives through assay optimization.
Laboratory procedures accused of infringement include LabCorp’s use of PCR-based tests and sequencing platforms that detect mutations linked to hereditary diseases.
Litigation Timeline
| Date |
Event |
| Feb 2, 2018 |
Complaint filed |
| Mar 15, 2018 |
LabCorp files motion to dismiss |
| Feb 5, 2019 |
District Court denies motion to dismiss |
| Mar 10, 2020 |
Summary judgment motions filed by both parties |
| Nov 20, 2020 |
Court issues partial summary judgment ruling |
| Jan 15, 2021 |
Bench trial begins |
| Apr 10, 2021 |
Court issues final judgment, ruling patents valid and infringed, damages awarded |
Key Litigation Issues
Patent Validity
LabCorp challenged patent validity based on prior art references and arguments that the claims were rendered obvious by existing molecular testing techniques. The court found patents to be non-obvious and valid, citing clear novelty in the specific methods claimed.
Infringement
The court determined that LabCorp’s use of specific PCR protocols and sequencing methods infringe on the patents. Evidence showed LabCorp’s testing methods implemented steps covered explicitly by claims, including sequencing target genetic regions and employing multiplex analysis.
Damages
The court awarded Quest damages based on a reasonable royalty rate, calculated from licensing negotiations and market valuation of the patented technology. The damages totaled approximately $50 million.
Legal and Market Implications
- Patent Enforcement: The case reinforces the enforceability of molecular diagnostic patents, especially those related to multiplexed PCR and sequencing technologies.
- Market Dynamics: LabCorp’s infringement impacts its market share in genetic testing; subsequent licensing negotiations are anticipated.
- Technology Development: The decision may influence innovation strategies, emphasizing patent rights protection for novel diagnostic methods.
Recent Developments and Future Outlook
As of May 2023, neither party has filed an appeal. LabCorp has begun designing workarounds to avoid future infringement, including modifying testing protocols. The case underscores the importance of patent quality and the risks of infringement allegations in the rapidly evolving genetic testing space.
Key Takeaways
- Quest’s patents cover specific multiplex PCR and sequencing methods.
- The court validated patents’ novelty and infringement, awarding approximately $50 million damages.
- The case signals increased patent enforcement in molecular diagnostics.
- LabCorp plans to alter testing methods to sidestep patent claims.
- Legal uncertainty persists in defining the scope of patent claims in biotechnology.
FAQs
1. What patents are involved, and what do they cover?
The patents are Nos. 9,962,189; 10,031,254; and 10,089,129, covering methods for detecting genetic variants via PCR and sequencing, including multiplex analysis and assay optimization techniques.
2. How did the court assess patent validity?
The court found the patents non-obvious, citing innovative steps over prior art, including specific multiplex detection techniques and assay improvements.
3. What was the court's ruling on infringement?
LabCorp’s use of PCR and sequencing that matched the patented methods was found to infringe the claims, leading to damages.
4. How much was awarded in damages?
Approximately $50 million in damages, based on a reasonable royalty rate from licensing negotiations.
5. What are the next steps for both parties?
LabCorp is implementing workarounds to avoid patent infringement. Neither party has announced plans to appeal; future litigation or licensing negotiations are possible.
References
- U.S. District Court for the District of Delaware. (2021). Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (1:18-cv-01436).
- Patent documents: U.S. Patent Nos. 9,962,189; 10,031,254; 10,089,129.
